3SOF

hi,
usually selling is based on the closing price and it closed above 14.40 at 14.57.
looks like a normal pullback on low volume.
thanks
maxi

Quote from: David Randolph on December 02, 2005, 08:02:18 AM
So, my stop loss order will be placed for a maximum 10% loss, that is, if the stock prints $14.40 today, I'll have to sell it and look for another opportunity, hopefully a better one.

He mentioned if it prints 14.40, hence a stop limit order throughout the day.

Quote from: ASR831 on December 04, 2005, 07:02:37 PM

Quote from: David Randolph on December 02, 2005, 08:02:18 AM
So, my stop loss order will be placed for a maximum 10% loss, that is, if the stock prints $14.40 today, I'll have to sell it and look for another opportunity, hopefully a better one.

He mentioned if it prints 14.40, hence a stop limit order throughout the day.

You got it right ASR831 when david mention "IF IT PRINTS" he probably put a limit order.
"IF IT PRINTS"  & "IF IT CLOSE"  are different..

 

I see a very clear distinction too.

"If it prints" means if that price is reached at any time.
"If it closes" or "if it is set to close" means just that. If earlier in the day it "prints" that price, then that is not a sell, only if it is set to close or closes at it.

Quote from: irod on December 05, 2005, 12:54:08 AM
I see a very clear distinction too.

"If it prints" means if that price is reached at any time.
"If it closes" or "if it is set to close" means just that. If earlier in the day it "prints" that price, then that is not a sell, only if it is set to close or closes at it.

You're right irod, BCRX was sold at $14.40, because the stock did «print» that price on Friday. It reached my limit loss of 10%, there was nothing I could do but to sell it, as planned. From now on I'll try to update the portfolio right after a transaction is made, so there's no confusion, though I think the plan was pretty explicit.

Good luck for anyone who continues to hold ...

A nice spark today.

UPDATE 1-BioCryst says FDA OKs human test of influenza drug
Thu Dec 22, 2005 09:01 AM ET
(Adds details, background, premarket stock activity; changes dateline, previously New York)

CHICAGO, Dec 22 (Reuters) - BioCryst Pharmaceuticals Inc. (BCRX.O: Quote, Profile, Research) on Thursday said the U.S. Food and Drug Administration has given verbal approval to begin human testing of intravenous peramivir, its influenza neuraminidase inhibitor, sending its shares up about 11 percent in premarket trading.

The Birmingham, Alabama-based company said the approval allows it to develop injectable formulations of peramivir. Early stage studies are expected to begin in the first quarter.

Separately, BioCryst also said it started early clinical trials of its lead anti-cancer compound Fodosine to determine the safety of repeat doses of an intravenous formulation of the drug in certain patient populations.

BioCryst shares were bid at $16.94 and offered at $16.95 in premarket trading, up from Wednesday's close at $15.21 on the Nasdaq.

uc.

Sure was. Was too late to get out    (my bank does not allow stop loss for the States) and figuered I'll just watch it till end of December, setting the absolute low at $ 14,21 (last bottom). Was a good strategy it appears now. Got out today with a small profit  and my Fast portfolio needs it... Still stuck with CIEN  Maybe that will play out nicely too 

Amarens

•Drugmaker shares rise on swine-flu outbreak
AP(Mon 5:47pm)


52wk Range: N/A - 4.00
Volume: 10,383,338
Avg Vol (3m): 62,139.7

Technicals
Close Above the 13-day MA
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
105.92%above 13-day MA
124.26%above 50-day MA
RS Rating: 57 

Fundamentals
Earnings Expected on May 7

Key Data:
Market Cap (M): $84.71 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/07/2009
Last Analyst Rating: Average

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3